CCL25 is the specific ligand of CCR9, and both were highly expressed in various types of cancer and activate multiple signaling pathways, especially the pathways related to drug resistance as well as metastasis, thus related to poor prognosis [36–40]. Here, CCR9 is linked to cancer.